Nuvo Pharmaceuticals Inc.

DB:23N Stock Report

Market Cap: €10.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals Management

Management criteria checks 4/4

Key information

Jesse Ledger

Chief executive officer

CA$753.5k

Total compensation

CEO salary percentage49.7%
CEO tenure6.3yrs
CEO ownership1.1%
Management average tenure6.3yrs
Board average tenure17.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jesse Ledger's remuneration changed compared to Nuvo Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2022n/an/a

CA$15m

Jun 30 2022n/an/a

-CA$3m

Mar 31 2022n/an/a

-CA$12m

Dec 31 2021CA$754kCA$375k

-CA$32m

Sep 30 2021n/an/a

-CA$24m

Jun 30 2021n/an/a

-CA$9m

Mar 31 2021n/an/a

-CA$20m

Dec 31 2020CA$577kCA$369k

-CA$4m

Sep 30 2020n/an/a

-CA$7m

Jun 30 2020n/an/a

CA$311k

Mar 31 2020n/an/a

CA$9m

Dec 31 2019CA$715kCA$350k

CA$3m

Sep 30 2019n/an/a

-CA$814k

Jun 30 2019n/an/a

-CA$8m

Mar 31 2019n/an/a

-CA$13m

Dec 31 2018CA$546kCA$350k

-CA$6m

Sep 30 2018n/an/a

-CA$2m

Jun 30 2018n/an/a

CA$473k

Mar 31 2018n/an/a

-CA$784k

Dec 31 2017CA$621kCA$292k

CA$2m

Sep 30 2017n/an/a

CA$4m

Jun 30 2017n/an/a

CA$5m

Mar 31 2017n/an/a

CA$8m

Dec 31 2016CA$300kCA$170k

CA$7m

Compensation vs Market: Jesse's total compensation ($USD549.24K) is about average for companies of similar size in the German market ($USD433.08K).

Compensation vs Earnings: Jesse's compensation has been consistent with company performance over the past year.

CEO

Jesse Ledger

6.3yrs

Tenure

CA$753,546

Compensation

Mr. Jesse F. Ledger has been the Chief Executive Officer of Nuvo Pharmaceuticals Inc. since November 21, 2017 and as its President since November 15, 2016. Mr. Ledger served as Vice President of Business D...

Leadership Team

NamePositionTenureCompensationOwnership
Jesse Ledger
President & CEO6.3yrsCA$753.55k1.09%
€ 114.7k
Mary-Jane Burkett
VP & CFO6.5yrsCA$394.05k0.14%
€ 15.0k
Bernard Chiasson
VP of Operations & Chief Scientific Officer5.5yrsCA$508.45k0.098%
€ 10.3k
Katina Loucaides
VP, Corporate Secretary & General Counselno dataCA$509.20k0.20%
€ 21.4k
Luigi Berardelli
Vice President of Sales & Marketingno dataCA$448.72kno data

6.3yrs

Average Tenure

Experienced Management: 23N's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Anthony Dobranowski
Independent Lead Director18.5yrsCA$66.75k0.61%
€ 64.9k
Rolf Zinkernagel
Member of Scientific Advisory Board17.5yrsno datano data
Stefan Meuer
Member of Scientific Advisory Board17.5yrsno datano data
Lee Simon
Member of Scientific Advisory Board17.5yrsno datano data
John London
Non-Executive Vice-Chairman18.5yrsCA$58.75k1.37%
€ 144.4k
Daniel Chicoine
Independent Director18.5yrsCA$60.75k2.07%
€ 218.6k
Mary Ritchie
Independent Director1.8yrsCA$36.86kno data
Jonathan Wilkin
Member of Scientific Advisory Boardno datano datano data
Dale Weil
Independent Directorless than a yearno datano data
Robert Harris
Non-Executive Chairman5.8yrsCA$93.33k0.66%
€ 69.5k
Anthony Snow
Directorless than a yearno datano data

17.5yrs

Average Tenure

67yo

Average Age

Experienced Board: 23N's board of directors are seasoned and experienced ( 17.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/17 13:06
End of Day Share Price 2023/03/16 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nuvo Pharmaceuticals Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Mark KnappClarus Securities Inc.
null nullEight Capital